In a subsequent phase 1 clinical trial (NCT01640301), a high-affinity WT1-specific TCR was inserted into Epstein-Bar virus-specific donor CD8+ T cells and twelve AML patients with poor-risk prophylactically received these WT1-specific TCR-T cells. This evidence concerns the gene CD8A and acute myeloid leukemia.